Recordati Valuation Multiples

Recordati Overview

About Recordati

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment which includes the production of active ingredients.

Founded

1926

HQ

Employees

4.6K

Website

recordati.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3B

EBITDA: $1B

EV

$13B

Valuation Multiples

Multiples.vc

Start free trial

Recordati Financials

Recordati reported last 12-month revenue of $3B and EBITDA of $1B.

In the same LTM period, Recordati generated $2B in gross profit, $1B in EBITDA, and $547M in net income.

Recordati P&L

In the most recent fiscal year, Recordati reported revenue of $3B and EBITDA of $918M.

Recordati expects next 12-month revenue of XXX and NTM EBITDA of XXX

Recordati Stock Performance

Recordati has current market cap of $11B, and enterprise value of $13B.

Recordati's stock price is $54.60.

Recordati Valuation Multiples

Recordati trades at 4.3x EV/Revenue multiple, and 11.5x EV/EBITDA.

Recordati Financial Valuation Multiples

As of March 19, 2026, Recordati has market cap of $11B and EV of $13B.

Equity research analysts estimate Recordati's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Recordati has a P/E ratio of 20.3x.

Recordati Margins & Growth Rates

Recordati's revenue in the last 12 month grew by 5%.

Recordati's revenue per employee in the last FY averaged $0.7M.

Recordati's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Recordati's rule of X is 49% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Recordati Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Recordati M&A Activity

Recordati acquired XXX companies to date.

Last acquisition by Recordati was on XXXXXXXX, XXXXX. Recordati acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Recordati Investment Activity

Recordati invested in XXX companies to date.

Recordati made its latest investment on XXXXXXXX, XXXXX. Recordati invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).